The Mid-Term Outcomes of Cone Repair or Replacement of Tricuspid Valve in Patients with Ebstein's Anomaly: Our Experience
DOI:
https://doi.org/10.1532/hsf.4165Keywords:
Ebstein's Anomaly, Cone Repair, Tricuspid Valve Repair / ReplacementAbstract
Background: Cone repair of the tricuspid valve (TV) is a contemporary reproducible technique for surgical reconstruction of Ebstein's anomaly. Different authorities have shown that this technique restores excellent tricuspid valve function. In Bangladesh, this technique still is unfamiliar to many. We hereby present a case series of cone repair and TV replacement with the mid-term outcome (one year to six years) at the National Heart Foundation Hospital & Research Institute, Dhaka, Bangladesh.
Methods: We prospectively studied 21 patients, who underwent surgical intervention (cone repair or tricuspid valve replacement) for Ebstein's anomaly of TV from March 2014 to June 2020. We divided the total patient population into the cone repair and TV replacement groups. Preoperative, postoperative, and follow-up data were collected from the hospital records, telephone conversations, and clinic visits. All collected data statistically were analyzed.
Results: Our patients showed there were statistically significant improvements after surgical intervention with regard to tricuspid regurgitation (TR) (P < 0.001), tricuspid annular plane systolic excursion (TAPSE) (P < 0.001), right ventricular (RV) function (P < 0.001), and New York Heart Association (NYHA) class (P < 0.001). These developments were sustained throughout the follow-up period.
Conclusion: Cone repair should be offered to the symptomatic patients of Ebstein's anomaly because symptoms relief, reduction of morbidity, and survival benefits are excellent. Above all, the cone reconstruction shows fantastic results and may well become the surgical technique for patients with Ebstein’s anomaly. We hope that new valve repair programs may provide extended longevity and restored quality of life to the patient of Ebstein's anomaly (EA) with the appropriate measures. In case of failed repair, valve replacement is an encouraging option.
References
Attenhofer Jost CH, Connolly HM, Scott CG, Burkhart HM, Ammash NM, Dearani JA. 2014. Increased risk of possible paradoxical embolic events in adults with Ebstein anomaly and severe tricuspid regurgitation. Congenit Heart Dis. 9:30–7.
Attenhofer Jost CH, Connolly HM, Scott CG, Burkhart HM, Warnes CA, Dearani JA. 2012. Outcome of cardiac surgery in patients 50 years of age or older with Ebstein anomaly: survival and functional improvement. J Am Coll Cardiol. 59:2101–6.
Attenhofer Jost CH, Edmister WD, Julsrud PR, et al. 2012. Prospective comparison of echocardiography versus cardiac magnetic resonance imaging in patients with Ebstein's anomaly. Int J Cardiovasc Imaging. 28:1147-59.
Badiu CC, Schreiber C, Hörer J, et al. 2010. Early timing of surgical intervention in patients with Ebstein's anomaly predicts superior long-term outcome. Eur J Cardiothorac Surg. 37(1):186-192.
Benson DW, Silberbach GM, Kavanaugh-McHugh A, et al. 1999. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest. 104(11):1567-1573.
Beroukhim RS, Jing L, Harrild DM, Fornwalt BK, Mejia-Spiegeler A, Rhodes J, et al. 2018. Impact of the cone operation on left ventricular size, function, and dyssynchrony in Ebstein anomaly: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 20(1):32.
Brown ML, Dearani JA, Danielson GK, et al. 2008. The outcomes of operations for 539 patients with Ebstein anomaly. J Thorac Cardiovasc Surg. 135(5):1120-1136.e11367.
Chauvaud SM, Hernigou AC, Mousseaux ER, Sidi D, Hebert JL. 2006. Ventricular volumes in Ebstein’s anomaly: X-ray multislice computed tomography before and after repair. Ann Thorac Surg. 81:1443–9.
Das Gupta S, Uddin M, Howlader SS, Kumar Biswas P, Kabiruzzaman M, Islam Talukder MQ. 2020. Surgical management for an adult, female patient, with Ebstein Anomaly on Tricuspid Valve that has Subvalvular membrane with severe PS and multiple VSDs-A case report. Heart Surg Forum. 23(6):E781-E785.
Dearani JA, Mora BN, Nelson TJ, Haile DT, O'Leary PW. 2015. Ebstein anomaly review: what's now, what's next? Expert Rev Cardiovasc Ther. 13(10):1101-1109.
Erin Fender, Chad J. Zack, Alexander Egbe. 2018. National trends and outcomes for surgical treatment of Ebstein’s anomaly. Mayo Clinic J Am Coll Cardiol. Mar, 71 (11 Supplement) A618.
Ghio S, Recusani F, Klersy C, et al. 2000. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 85:837-42.
Goleski PJ, Sheehan FH, Chen SS, Kilner PJ, Gatzoulis MA. 2014. The shape and function of the left ventricle in Ebstein's anomaly. Int J Cardiol. 171(3):404-12.
Holst KA, Dearani JA, Said S, Pike RB, Connolly HM, Cannon BC, et al. 2018. Improving results of surgery for Ebstein anomaly: where are we after 235 cone repairs? Ann Thorac Surg. 105(1):160-8.
Hunter SW, Lillehei CW. 1958. Ebstein malformation of the tricuspid valve. Study of a case together with suggestions of a new form of surgical therapy. Dis Chest. 33(3):297-304.
Kaul S, Tei C, Hopkins JM, et al. 1984. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J. 107:526-31.
Lang RM, Bierig M, Devereux RB, et al. 2005. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 18:1440-63.
Lange R, Burri M, Eschenbach LK, Badiu CC, da Silva JP, Nagdyman N, et al. 2015. Da Silva’s cone repair for Ebstein’s anomaly: effect on right ventricular size and function. Eur J Cardiothorac Surg. 48(2):316-21; discussion 320-1.
Li X, Wang SM, Schreiber C, Cheng W, Lin K, Sun JY, et al. 2016. More than valve repair: effect of cone reconstruction on right ventricular geometry and function in patients with Ebstein anomaly. Int J Cardiol. 206:131-7.
Liu J, Qiu L, Zhu Z, Chen H, Hong H. 2011. Cone reconstruction of the tricuspid valve in Ebstein anomaly with or without one and a half ventricle repair. J Thorac Cardiovasc Surg. 141(5):1178-83.
Malhotra SP, Petrossian E, Reddy VM, Qiu M, Maeda K, Suleman S, et al. 2009. Selective right ventricular unloading and novel technical concepts in Ebstein’s anomaly. Ann Thorac Surg. 88:1975–81.
Mrad Agua K, Burri M, Cleuziou J, et al. 2019. Preoperative predictability of right ventricular failure following surgery for Ebstein's anomaly. Eur J Cardiothorac Surg. 55(6):1187-1193.
Postma AV, van Engelen K, van de Meerakker J, et al. 2011. Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ Cardiovasc Genet. 4(1):43-50.
Raju V, Dearani JA, Burkhart HM, et al. 2014. Right ventricular unloading for heart failure related to Ebstein malformation. Ann Thorac Surg. 98:167-73; discussion 173-4.
Said SM, Burkhart HM, Schaff HV, et al. 2014. When should a mechanical tricuspid valve replacement be considered? J Thorac Cardiovasc Surg. 148:603-8.
Saxena A, Relan J, Agarwal R, et al. 2019. Indian guidelines for indications and timing of intervention for common congenital heart diseases: Revised and updated consensus statement of the Working group on management of congenital heart diseases. Ann Pediatr Cardiol. 12(3):254-286.
Silva GVRD, Miana LA, Caneo LF, et al. 2019. Early and Long-Term Outcomes of Surgical Treatment of Ebstein's Anomaly. Braz J Cardiovasc Surg. 34(5):511-516. Published Dec 1.
Silva JP, Baumgratz JF, Fonseca Ld, et al. 2004. Anomalia de Ebstein: resultados com a reconstrução cônica da valva tricúspide [Ebstein's anomaly: results of the conic reconstruction of the tricuspid valve]. Arq Bras Cardiol. 82(3):212-216.
Taggart NW, Cabalka AK, Eicken A, et al. 2018. Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly. Am J Cardiol. 121:262-8.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
